HER2-positive breast cancer: Incidence, prognosis, and treatment options

American Journal of Cancer

Volumn 2, Issue 3, 2003, Pages 169-179

  Estévez, Laura G ^a   Seidman, Andrew D ^b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GENE PRODUCT; MEMBRANE PROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; NAVELBINE; PACLITAXEL; THIOTEPA; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

ALOPECIA; BLOOD TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SIZE; CARDIOTOXICITY; CHILL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; MORTALITY; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0038711290     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302030-00002     Document Type: Review

References (63)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistic, 2001. CA Cancer J Clin 2001; 51: 15-36
2. Herderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al., editors. Breast diseases. Philadelphia (PA): J.B. Lippincott Company, 1991: 604-65
3. Vogel CI, Azevedo S, Hilsenbeck S, et al. Survival after first recurrence of breast cancer: the Miami experience. Cancer 1992; 70: 129-35
4. Padhy LC, Shih C, Cowing D, et al. Identification of a phosphoprotein specifically induced by the transformation DNA of rat neuroblatomas. Cell 1982; 28: 865-71
5. Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-4
6. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogen is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986; 6: 1729-40
7. Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogen. Science 1985; 230: 1132-9
8. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10: 1813-21
9. Mansour SJ, Matteu WT, Hermann AS, et al. Transformation of mammalians cells by constitutively active MAP kinase. Science 1994; 265: 966-70
10. Carraway KL, Soltoff SP, Diamonti AJ, et al. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 1995; 270: 7111-6
11. Fincham V, Frame M, Haefner B, et al. Functions of the v-Src protein tyrosine kinase. Cell Biol Int 1994; 18: 337-44
12. Jove R, Hanafusa H. Cell transformation by the viral src oncogene. Ann Rev Cell Biol 1987; 3: 31-56
13. Muthuswamy SK, Siegel PM, Dankort DL, et al. Mammary tumors expressing the neu proto-oncogen posses elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14: 735-43
14. Xie Y, Li K, Hung MC. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. Oncogene 1995; 10: 2409-13
15. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177-82
16. Hynes NE, Stern DF. The biology of crbB2/ncu/HER-2 and its role in cancer. Biochem Biophys Acta 1994; 1198: 165-84
17. Rubin I, Yarden Y. The basic biology of Her 2. Ann Oncol 2001; 12 Suppl. 1: 3-8
18. Hudziak RM, Lewis GD, Winget M, et al. p185HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumors to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-72
19. HER2 antibody. Am J Respir Cell Mol Biol 1993; 9: 448-54
20. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24: 85-95
21. HER2 signal transduction in breast cancer cells. J Biol Chem 1991; 266 (22): 14300-5
22. HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255-63
23. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991; 11: 117-27
24. Yardem Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U S A 1990; 87: 2569-73
25. Park JW, Stagg R, Lewis GD, et al. Anti-p185Her2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treatment Res 1992; 61: 193-211
26. Maier LA, Xu FJ, Hester S, et al. Requirements for the internalization of a murine monoclonal antibody directed against the Her-2/neu gene product c-erbB-2. Cancer Res 1991; 51: 5361-9
27. Klapper LN, Vaisman N, Hurwitz E, et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/Her2 blocks crosstalk with growth factor receptors. Oncogene 1997; 14: 2099-109
28. Rodriguez GC, Boente MP, Berchuck A, et al. The effect of antibodies and immunotoxins reactive with Her2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 1993; 168: 228-32
29. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to Her2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-38
30. Arteaga CL, Winnier AR, Poirier MC, et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994; 54: 3758-65
31. Carter P, Gorman CD, Presta L, et al. Humanization of an anti-p185HER-2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285-9
32. Baly DL, Wirth CM, Allison DA, et al. Development and characterization of a rhuMAbHer2 antibody assay for clinical evaluation of cytotoxic potency [abstract 181]. Proc Am Assoc Cancer Res 1997; 38: 27
33. Pegram MD, Baly D, Wirth C, et al. Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase II clinical trials of a humanized anti-HER2 antibody [abstract 4044]. Proc Am Assoc Cancer Res 1997; 38: 602
34. Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human growth factor receptor of Her2/neu gene product. Cancer Res 1990; 50: 1550-8
35. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the cerbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-80
36. Harwerth IM, Wels W, Schlegel J, et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth. Br J Cancer 1993; 68: 1140-5
37. Mckenzie SJ, Marks PJ, Lam T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989; 4: 543-8
38. HER2 monoclonal antibody that stimulates receptor functions and inhibits tumor cell growth. Growth Regul 1991; 1: 72-82
39. Stancovski I, Kurwitz E, Leitner O, et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumor growth. Proc Natl Acad Sci U S A 1991; 88: 8691-5
40. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combination of Her-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-51
41. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17: 2235-49
42. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31
43. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer: for the Herceptin® Multinational Investigator Study Group. Semin Oncol 1999; 26 (12 Suppl.): 71-7
44. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44
45. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48
46. Vogel C, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single-agent in first line treatment of Her2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26
47. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-71
48. Scidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 inmunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-95
49. Scidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-61
50. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30
51. Esteva FJ, Valero V, Booser D, et al. A phase II trial of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing (HER2+) metastatic breast cancer. J Clin Oncol 2002; 20: 1800-8
52. Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel and Herceptin as first- or second-line treatment in HER2 over-expressing metastatic breast cancer [abstract 1949]. Pro Am Soc Clin Oncol 2001; 20: 50b
53. Slamon DJ, Ravindranath P, Northfelt R, et al. Phase II pilot study of Herceptin® combined with taxoterc and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-neu proto-oncogene: a pilot study of the UCLA Network [abstract 193]. Pro Am Soc Clin Oncol 2001; 20: 49a
54. Meden H, Beneke A, Hesse T, et al. Weekly intravenous recombinant humanized anti-Her2 monoclonal antibody (trastuzumab) plus docetaxel in patients with metastatic breast cancer: a pilot study [abstract 1987]. Pro Am Soc Clin Oncol 2001; 20: 60b
55. Pienkowski T, Fumoleau P, Eirmann W, et al. Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients: a phase II pilot study by the breast cancer international research group (BCIRG 101) [abstract 2030]. Pro Am Soc Clin Oncol 2001; 20: 70b
56. Kuzur ME, Albain KS, Huntington MO, et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing Her-2 [abstract]. Proc Am Soc Clin Oncol 2000; 19: 512a
57. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
58. Seidman AD, Hudis C, Keefe D, et al. Characterization of cardiac dysfunction in the Herceptin clinical trials experience. J Clin Oncol 2002; 20: 1215-21
59. Tripathy D, Slamon D, Leyland-Jones B, et al. Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial [abstract 25]. Breast Cancer Res Treat 2000; 64: 32
60. Gelmon K, Arnold A, Verma S, et al. Pharmacokinetics and safety of trastuzumab (Herceptin®) when administered every three weeks to women with metastatic breast cancer [abstract 271]. Pro Am Soc Clin Oncol 2001; 20: 69a
61. Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001; 28 (3 Suppl.): 1-12
62. Piccart M. Closing remarks and treatment guidelines. Eur J Cancer 2001; 37: 30-3
63. Mass RD, Sanders C, Charlene K, et al. The concordance between the clinical trials assays (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin® pivotal trials [abstract]. Pro Am Soc Clin Oncol 2000; 19: 291a